Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY: RMD )

243.46 -14.19 (-5.51%)
Streaming Delayed Price Updated: 12:28 PM EST, Jan 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,278,637
Open 258.00
Bid (Size) 243.34 (1)
Ask (Size) 243.71 (2)
Prev. Close 257.65
Today's Range 235.00 - 259.95
52wk Range 170.56 - 263.05
Shares Outstanding 146,234,244
Dividend Yield 0.87%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Friday's session: gap up and gap down stock in the S&P500 index
Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
ResMed: Digital Health Drives Q2 Growth
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability. 
Via The Motley Fool

Performance

YTD
+6.56%
+6.56%
1 Month
+6.46%
+6.46%
3 Month
+0.41%
+0.41%
6 Month
+13.47%
+13.47%
1 Year
+28.00%
+28.00%

More News

Read More
ResMed Earnings Analysis: Q2 Recap
Via Benzinga
ResMed, In A Buy Zone, Stays Flat After Handily Beating Earnings Views
Via Investor's Business Daily
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025
From ResMed Inc.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About ResMed
Via Benzinga
Should you consider RESMED INC (NYSE:RMD) for quality investing?
Via Chartmill
Why Quality-Oriented Investors Should Consider NYSE:RMD.
Via Chartmill
Wall Street Remains Flat, Microsoft Eyes Heaviest Drop Since Late 2022, Gold Sets Fresh Records: What's Driving Markets Thursday?
Via Benzinga
Reasonable Growth, Debt Levels, and a High ROIC Make RESMED INC (NYSE:RMD) Appealing to Quality Investors.
Via Chartmill
This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
P/E Ratio Insights for ResMed
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For ResMed
Via Benzinga
Earnings Scheduled For January 30, 2025
Via Benzinga
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
Top Stock Reports For UnitedHealth, Costco & IBM
Via Talk Markets
Topics Stocks / Equities
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Via Investor's Business Daily
Exposures Product Safety
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
Via Investor's Business Daily
ResMed Announces Participation in the UBS Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
Via Investor's Business Daily
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Via Benzinga
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
Via Benzinga
My 3 Favorite Stocks to Buy Right Now
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.